Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification

Clinical Biochemistry

Volumn 47, Issue 18, 2014, Pages 272-278

  Pérez de Ciriza, Carmen ^a   Moreno, María ^a   Restituto, Patricia ^a   Bastarrika, Gorka ^a   Simón, Isabel ^a   Colina, Inmaculada ^a   Varo, Nerea ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Adipose tissue; Atherosclerosis; Coronary calcification; Metabolic syndrome; Osteoprotegerin

Indexed keywords

BETA ACTIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ABDOMINAL FAT; ADIPOSE TISSUE; ADULT; AGE; ARTERIAL PRESSURE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; COMMON CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; BLOOD VESSEL CALCIFICATION; COMPLICATION; CORONARY ARTERY DISEASE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED;

ADIPOSE TISSUE; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY DISEASE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OSTEOPROTEGERIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR CALCIFICATION;

EID: 84921319456     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.09.004     Document Type: Article

References (34)

1. Venuraju S.M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010, 55(19):2049-2061.
2. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292(4):490-495.
3. Caidahl K., Ueland T., Aukrust P. Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol 2010, 30(9):1684-1686.
4. Schoppet M., Kavurma M.M., Hofbauer L.C., Shanahan C.M. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochem Biophys Res Commun 2011, 407(1):103-107.
5. Zannettino A.C., Holding C.A., Diamond P., Atkins G.J., Kostakis P., Farrugia A., et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005, 204(2):714-723.
6. Chollet M.E., Brouland J.P., Bal Dit Sollier C., Bauduer F., Drouet L., Bellucci S. Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets. Br J Haematol 2010, 148(5):805-807.
7. Bitto A., De Caridi G., Polito F., Calo M., Irrera N., Altavilla D., et al. Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques. J Vasc Surg 2010, 52(4):1015-1021.
8. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109(18):2175-2180.
9. Vik A., Mathiesen E.B., Brox J., Wilsgaard T., Njolstad I., Jorgensen L., et al. Relation between serum osteoprotegerin and carotid intima media thickness in a general population-the Tromso Study. J Thromb Haemost 2010, 8(10):2133-2139.
10. Vik A., Mathiesen E.B., Brox J., Wilsgaard T., Njolstad I., Jorgensen L., et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost 2011, 9(4):638-644.
11. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J.F., et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010, 30(9):1849-1854.
12. Akinci B., Celtik A., Yuksel F., Genc S., Yener S., Secil M., et al. Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. Diabetes Res Clin Pract 2011, 91(1):26-31.
13. Nabipour I., Kalantarhormozi M., Larijani B., Assadi M., Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010, 59(5):742-747.
14. Augoulea A., Vrachnis N., Lambrinoudaki I., Dafopoulos K., Iliodromiti Z., Daniilidis A., et al. Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol 2013, 2013:182060.
15. O'Sullivan E.P., Ashley D.T., Davenport C., Devlin N., Crowley R., Agha A., et al. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab Res Rev 2010, 26(6):496-502.
16. Stepien E., Wypasek E., Stopyra K., Konieczynska M., Przybylo M., Pasowicz M., et al. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem 2011, 44(10-11):826-831.
17. Blazquez-Medela A.M., Garcia-Ortiz L, Gomez-Marcos M.A., Recio-Rodriguez J.I., Sanchez-Rodriguez A., Lopez-Novoa J.M., et al. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Investig 2012, 42(5):548-556.
18. Giorgetti A.P., Cesar Neto J.B, Ruiz K.G., Casati M.Z., Sallum E.A., Nociti F.H. Cigarette smoke inhalation modulates gene expression in sites of bone healing: a study in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2012, 110(4):447-452.
19. Tang T.H., Fitzsimmons T.R., Bartold P.M. Effect of smoking on concentrations of receptor activator of nuclear factor kappa B ligand and osteoprotegerin in human gingival crevicular fluid. J Clin Periodontol 2009, 36(9):713-718.
20. Ashley D.T., O'Sullivan E.P., Davenport C., Devlin N., Crowley R.K., McCaffrey N., et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism 2011, 60(7):994-1000.
21. Secchiero P., Corallini F., Pandolfi A., Consoli A., Candido R., Fabris B., et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006, 169(6):2236-2244.
22. Morony S., Tintut Y., Zhang Z., Cattley R.C., Van G., Dwyer D., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008, 117(3):411-420.
23. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204(2):321-329.
24. Golledge J., McCann M., Mangan S., Lam A., Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004, 35(7):1636-1641.
25. Heymann M.F., Herisson F., Davaine J.M., Charrier C., Battaglia S., Passuti N., et al. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine 2012, 58(2):300-306.
26. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S.A., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99(4):513-518.
27. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12(9):1260-1268.
28. Bennett B.J., Scatena M., Kirk E.A., Rattazzi M., Varon R.M., Averill M., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006, 26(9):2117-2124.
29. Gomez-Ambrosi J., Rodriguez A., Catalan V., Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg 2008, 18(9):1134-1143.
30. An J.J., Han D.H., Kim D.M., Kim S.H., Rhee Y., Lee E.J., et al. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J 2007, 48(5):765-772.
31. Harslof T., Husted L.B., Carstens M., Stenkjaer L., Sorensen L., Pedersen S.B., et al. The expression and regulation of bone-acting cytokines in human peripheral adipose tissue in organ culture. Horm Metab Res 2011, 43(7):477-482.
32. Fain J.N., Tagele B.M., Cheema P., Madan A.K., Tichansky D.S. Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women. Obesity (Silver Spring) 2010, 18(5):890-896.
33. Vik A., Mathiesen E.B., Johnsen S.H., Brox J., Wilsgaard T., Njolstad I., et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population-the Tromso study. J Thromb Haemost 2010, 8(5):898-905.
34. Yeboah J., Delaney J.A., Nance R., McClelland R.L., Polak J.F., Sibley C.T., et al. Mediation of cardiovascular risk factor effects through subclinical vascular disease. The multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2014, 34:1778-1783.